Claims for Patent: 6,423,693

Summary for Patent: 6,423,693

Title:	Growth hormone releasing hormone expression system and methods of use, including use in animals
Abstract:	Vectors which establish controlled expression of recombinant GHRH genes within tissues at certain levels. The vector includes a 5\' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a 3\' flanking region including a 3\'UTR and/or 3\'NCR, and a linker which connects the 5\' flanking region to a nucleic acid sequence. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. The 3\' flanking region is 3\' to the position for inserting the nucleic acid cassette.
Inventor(s):	Schwartz; Robert J. (Houston, TX), Draghia-Akli; Ruxandra (Houston, TX), Li; Xuyang (Lewisville, TX), Eastman; Eric M. (Highland, MD)
Assignee:	Baylor College of Medicine (Houston, TX) Valentis, Inc. (Burlingname, CA)
Application Number:	09/122,171
Patent Claims:	1. A vector for expression of a nucleic acid sequence in a cell, comprising: a nucleic acid cassette comprising a nucleotide sequence encoding a growth hormone releasing hormone ("GHRH"); a 5' flanking region including one or more sequences necessary for expression of said nucleic acid cassette, wherein said sequences include a promoter, a linker nucleic acid sequence linking said 5' flanking region to a nucleic acid, said linker nucleic acid sequence comprising a site for inserting said nucleic acid cassette, wherein said linker nucleic acid sequence lacks the coding sequence of a gene with which it is naturally associated; and a 3' flanking region operably linked to said linker nucleic acid sequence, wherein the 3' flanking region comprises a 3' untranslated region ("UTR") or a 3' noncoding region ("NCR") or both, wherein said 3' flanking region is 3' to said site for inserting said nucleic acid cassette, wherein said nucleotide sequence encoding said GHRM is a synthetic sequence encoding a human GHRH wherein said human GHRH has the sequence of SEQ ID NO: 2. 2. The vector of claim 1, wherein said promoter is a promoter from a skeletal .alpha.-actin gene. 3. The vector of claim 2, wherein said promoter is from a chicken skeletal .alpha.-actin gene. 4. The vector of claim 2, wherein said promoter is from a human skeletal .alpha.-actin gene. 5. The vector of claim 1, wherein said 3'-UTR is a growth hormone 3'-UTR. 6. The vector of claim 5, wherein said growth hormone 3'-UTR is from a human growth hormone gene. 7. The vector of claim 5, wherein an ALU repeat or ALU repeat-like sequence is deleted from said 3'UTR. 8. The vector of claim 1, wherein said GHRH is human GHRH, said promoter is from a chicken skeletal .alpha.-actin gene, and said 3'-UTR is from a human growth hormone gene. 9. The vector of claim 1, wherein said 5' flanking region or said 3' flanking region or both regulates expression of said nucleic acid cassette predominatly in a specific tissue. 10. The vector of claim 9, wherein said specific tissue is myogenic. 11. The vector of claim 1, wherein said 5' flaking region comprises a promoter, a TATA box, a Cap site and a first intron and intronlexon boundary in operable linkage for expression of said nucleic acid cassette. 12. The vector of claim 11, wherein said 5' flanking region further comprises a 5' mRNA leader sequence inserted between said promoter and said nucleic acid cassette. 13. The vector of claim 1, wherein said vector further comprises a 5'UTR sequence of a chicken skeletal .alpha.-actin gene. 14. The vector of claim 1, wherein said vector further comprises an antibiotic resistance gene. 15. A formulation for delivery and expression of a human GHRH gene in a muscle cell in vivo, said formulation comprising the vector of claim 1 and a stabilizing or transfection enhancing component selected from the group consisting of: polyvinyl pyrrolidone ("PVP"), cationic lipid and neutral-co-lipid. 16. The formulation of claim 15, wherein said stabilizing or transfection enhancing component includes about 5% PVP. 17. A cell transformed in vitro with the vector of claim 1. 18. The transformed cell of claim 17, wherein said cell is a myoblast. 19. A method for tranfection of a cell in vitro, comprising the step of contacting said cell with the vector of claim 1 for sufficient time to transfect said cell. 20. The method of claim 19, wherein transfection of said cell is performed ex vivo, further comprising the steps of cotransfecting said vector with a selectable marker and selecting the transformed cells. 21. A method for transfection of a muscle cell in vivo, comprising the step of administering directly to said cell the vector of claim 1 for sufficient time to transfect said cell. 22. The method of claim 21, wherein said contacting is performed in the presence of an about 5% PVP solution. 23. A method for delivery and expression of a GHRH gene in a plurality of muscle cells, comprising the steps of: (a) administering directly to said plurality of muscle cells the vector of claim 1; and (b) incubating said plurality of muscle cells under conditions that allow the expression of the nucleotide sequence encoding the GHRH in said vector. 24. The method of claim 23, wherein said cells are human cells. 25. The method of claim 24, wherein said transfecting is performed in the presence of an about 5% PVP solution. 26. The vector of claim 1, wherein said vector comprises a nucleotide sequence which is the same as the nucleotide sequence of plasmid pSK-GHRH.

Details for Patent 6,423,693

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-07-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-07-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-07-24